Title: Methods for Predicting and Overcoming Resistance to Chemotherapy in Ovarian Cancer and for Predicting Colon Cancer Occurrence
Number: 20050176669
Filed: Dec. 30, 2004
Lead Inventor: Samer Al-Murrani, Pennsylvania State University
According to the patent application's abstract, "the invention provides methods for predicting whether an ovarian cancer patient's tumor will be resistant to chemotherapy. The invention also provides methods for monitoring the effectiveness of treatment, particularly a chemotherapeutic treatment, in a patient treated for ovarian cancer. The invention further provides methods for treating ovarian cancer, by reducing chemotherapeutic drug resistance in said cells," the abstract states. "In addition, the invention provides methods of screening compounds to identify tumor cell growth inhibitors in tumor cells resistant to conventional chemotherapeutic treatment regimes."
The application specifically claims the use of an siRNA or shRNA to modulate a cellular gene.
Title: Compositions and Methods for Inhibiting Expression of Anti-Apoptotic Genes
Number: 20050176667
Filed: Sept. 15, 2004
Lead Inventor: Hans-Peter Vornlocher, Alnylam Europe
The invention, the patent application states, "relates to a double-stranded ribonucleic acid for inhibiting the expression of an anti-apoptotic gene, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of an apoptotic gene, such as a Bcl gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of an anti-apoptotic gene using the pharmaceutical composition; and methods for inhibiting the expression of an anti-apoptotic gene in a cell."
Title: RNA Interference-Mediated Inhibition of GPRA and AAA1 Gene Expression Using Short Interfering Nucleic Acid
Number: 20050176666
Filed: Aug. 20, 2004
Lead Inventor: Ivan Richards, Sirna Therapeutics
"This invention relates to compounds, compositions, and methods useful for modulating G protein-coupled receptor for asthma susceptibility (GPRA) and asthma-associated alternatively spliced gene 1 (AAA1) gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of GPRA and/or AAA1 gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of GPRA and/or AAA1 genes."
Title: RNA Interference-Mediated Inhibition of Hairless (HR) Gene Expression Using Short Interfering Nucleic Acid
Number: 20050176665
Filed: Aug. 17, 2004
Inventor: James McSwiggen, Sirna Therapeutics
"This invention relates to compounds, compositions, and methods useful for modulating Hairless (HR) gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of Hairless gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of Hairless."
Title: RNA Interference-Mediated Inhibition of Cholinergic Muscarinic Receptor (CHRM3) Gene Expression Using Short Interfering Nucleic Acid
Number: 20050176664
Filed: Aug. 17, 2004
Lead Inventor: Ivan Richards, Sirna Therapeutics
According to the patent application's abstract, the invention "relates to compounds, compositions, and methods useful for modulating cholinergic muscarinic receptor gene expression using short interfering nucleic acid molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of cholinergic muscarinic receptor gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of cholinergic muscarinic receptor genes, such as M3 muscarinic acetylcholine receptor or cholinergic receptor muscarinic 3."
Title: RNA Interference-Mediated Inhibition of Protein Tyrosine Phosphatase Type IVA (PRL3) Gene Expression Using Short Interfering Nucleic Acid
Number: 20050176663
Filed: July 23, 2004
Lead Inventor: James McSwiggen, Sirna Therapeutics
"This invention," the patent application's abstract states, "relates to compounds, compositions, and methods useful for modulating protein tyrosine phosphatase type IVA gene expression using short interfering nucleic acid molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of protein tyrosine phosphatase type IVA gene expression and/or activity by RNA interference using small nucleic acid molecules," the abstract notes. "In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of protein tyrosine phosphatase type IVA genes."
Title: Methods and Compositions for Detecting and Treating Retinal Diseases
Number: 20050176662
Filed: Feb. 9, 2004
Lead Inventor: George Inana, University of Miami
"The invention discloses multiple genes related to age-related macular degeneration and/or phagocytosis by RPE cells of the eye, and methods and compositions for detecting and treating AMD and other retinal degenerative conditions based on these phagocytosis-related and/or AMD-related genes," the patent application's abstract notes. "Also provided are animal models useful for testing therapeutic compounds and treatment protocols for AMD, and gene arrays including polymorphic variants of phagocytosis-related and/or AMD-related genes, useful for genetic screening of nucleic acid samples from subjects to obtain profiles of polymorphic variant sequences in a plurality of genes associated with AMD."
Title: SNP Discriminatory siRNA
Number: 20050176045
Filed: Jan. 25, 2005
Lead Inventor: Yuriy Federov, Dharmacon
According to the patent application's abstract, the invention is "a method of identifying SNP-specific siRNA. The method comprises comparing the silencing effect of: at least two SNP-containing siRNA in cells that contain a SNP target sequence; [the] SNP-containing siRNA in cells that contain a wild type target sequence; at least two non-SNP containing siRNA in cells that contain a SNP target sequence; and [the] non-SNP containing siRNA in cells that contain a wild type target sequence. Through the method, SNP-specific siRNA can be selected for a diverse set of genes, including the Kras gene," the abstract states.
Title: RNA Interference-Mediated Inhibition of Epidermal Growth Factor Receptor Gene Expression Using Short Interfering Nucleic Acid
Number: 20050176024
Filed: Aug. 20, 2004
Lead Inventor: James McSwiggen, Sirna Therapeutics
"This invention relates to compounds, compositions, and methods useful for modulating epidermal growth factor receptor (EGFR) (e.g., HER1, HER2, HER3, and/or HER4) gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of EGFR gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of EGFR genes, including HER 1, HER2, HER3, and/or HER4. The small nucleic acid molecules are useful in the treatment and diagnosis of cancer," the abstract adds.
Title: RNA Interference-Mediated Inhibition of B-Cell CLL/Lymphoma-2 (BCL-2) Gene Expression Using Short Interfering Nucleic Acid
Number: 20050176025
Filed: Aug. 20, 2004
Lead Inventor: James McSwiggen, Sirna Therapeutics
According to the patent application's abstract, the invention "relates to compounds, compositions, and methods useful for modulating BCL2 gene expression using short interfering nucleic acid molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of BCL2 gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA, double-stranded RNA, microRNA, and short hairpin RNA molecules and methods used to modulate the expression of BCL2 genes (e.g., BCL2, BCL-XL, BCL2-L1, MCL-1 CED-9, BAG-1, E1B-194 and/or BCL-A1)," the abstract states. "The small nucleic acid molecules are useful in the treatment of cancer, malignant blood disease, polycytemia vera, idiopathic myelofibrosis, essential thrombocythemia, myelodysplastic syndromes, autoimmune disease, viral infection, and proliferative diseases and conditions."